Damora Therapeutics is trading 5.34% higher at $19.43 on October 19, 2026; no company-specific explanation for the rise surfaced in available search.
- The company’s investor-relations page lists an October 2 employee inducement-grant release as its latest news.
- Supplied market reports describe a tech-sector rebound and an early sell-off followed by recovery. Neither establishes a direct reason for the stock’s move, and the catalyst remains unclear.